<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health</h1>

    <table>
      <tr><th>Ticker</th><td>ELAB</td></tr>
      <tr><th>Float</th><td>1.1 M</td></tr>
      <tr><th>IO</th><td>0.05%</td></tr>
      <tr><th>MC</th><td>2.9 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>PMGC Holdings' subsidiary NorthStrive Biosciences executed a definitive, exclusive license agreement with Modulant Biosciences granting Modulant an exclusive, royalty-bearing, sublicensable worldwide (excluding South Korea) license to develop, manufacture and commercialize EL-22 and EL-32-derived products for non-human animal health (including feed additives). The license covers issued patents, pending applications and know-how; Modulant is responsible for development, manufacturing, regulatory and commercialization efforts and may grant sublicenses. The agreement excludes human pharmaceutical/clinical applications and provides for shared ownership of improvements. Financial terms are described as value paid to NorthStrive but specific amounts are not disclosed. Company notes that there is no assurance Modulant will successfully develop, obtain approvals for, or commercialize products.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Exclusive, sublicensable worldwide (ex-Korea) license converts prior term sheet into a definitive agreement</li><li>License covers issued patents, pending applications and proprietary know‑how for EL-22 and EL-32</li><li>Modulant assumes responsibility for development, manufacturing, regulatory and commercialization activities</li><li>Agreement allows sublicensing and includes shared ownership of improvements/new IP</li><li>Targets the growing animal health and feed additive markets (livestock, companion animals)</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Financial terms and milestone/payment details not disclosed in the release</li><li>License explicitly excludes human pharmaceutical/clinical applications, limiting potential markets</li><li>No assurance Modulant will achieve regulatory approvals, successful development, or market acceptance</li><li>Republic of Korea excluded from the license territory, reducing geographic scope</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/ea6c30ea-3d42-4071-b6fd-94f676bbd8f7" target="_blank">Original Article</a>
    </div>

    <div class="small">ELAB • TradersLink AI News</div>
  </div>
</body>
</html>